Watch CBIO. Know when insiders buy.
One email the day a filing lands. Free.
CBIO
CRESCENT BIOPHARMA, INC.
19.99
−0.47 −2.30%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
69
PASS · shorts 69
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $742.5MP/E —DIV YIELD —FCF YIELD -9.91%REV TTM —NET INCOME −$96MNET CASH —52W 8.94 – 26.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$26.4M | −$24.8M | — | — | −$19.5M | $13K | −$19.5M | Jul 30 |
| Q1 2026 · Mar 31 | $1M | — | — | −$24.7M | −$23.3M | — | — | −$8.9M | $147K | −$9.1M | Jul 30 |
| Q4 2025 · Dec 31 | — | — | — | −$91.5M | −$23.3M | — | — | −$26.7M | $193K | −$26.9M | Apr 29 |
| Q3 2025 · Sep 30 | — | — | — | −$25.9M | −$24.6M | — | — | −$17.5M | $586K | −$18.1M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$21M | −$21.8M | — | — | −$16.4M | $140K | −$16.5M | Jul 30 |
| Q1 2025 · Mar 31 | $0 | — | — | −$14.2M | −$15.1M | — | -0.04 | −$10.9M | $0 | −$10.9M | Jul 30 |
| Q4 2024 · Dec 31 | $0 | — | — | −$17.2M | −$17.9M | — | -0.11 | −$6.3M | $0 | −$6.3M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$11.2M | −$9.8M | — | -0.15 | −$8M | $0 | −$8M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$10.4M | −$10.1M | — | -0.16 | −$8.9M | $3K | −$8.9M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$11.1M | −$10.7M | — | -0.04 | −$10.5M | $7K | −$10.5M | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.6M | −$9.1M | — | -0.14 | −$7.6M | $801 | −$7.6M | Feb 13 |
| Q3 2023 · Sep 30 | — | — | — | −$9.8M | −$9.2M | — | -0.14 | −$8.7M | $8K | −$8.7M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $10.8M | — | −$152.6M | −$153.9M | -1419.6% | — | −$71.5M | $919K | −$72.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$40M | −$37.9M | — | -0.59 | −$31.1M | $10K | −$31.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$39.3M | −$36.9M | — | -0.58 | −$34.9M | $21K | −$34.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$47.4M | −$46.7M | — | -0.89 | −$46.5M | $84K | −$46.5M | — | — |
| FY2021 · to Dec 31 | — | — | −$63.4M | −$63.4M | — | -1.23 | −$57.5M | $15K | −$57.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$51.5M | −$51M | — | -1.12 | −$39.2M | $69K | −$39.3M | — | — |
Every number comes from CRESCENT BIOPHARMA, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.